MitoQ Ltd is a wholly owned subsidiary of Antipodean Pharmaceuticals Inc, a biotechnology company that holds worldwide patents to a class of mitochondiria-targetd antioxidants. Mitoquinol Mesylate has the benefit of over a decade and 60 million USD of research resulting in over 200 published research papers investigating its effect across a wide range of disease models and in aging.